A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DUAL™ II China
- Sponsors Novo Nordisk
- 14 May 2018 Planned End Date changed from 14 Jan 2019 to 13 May 2019.
- 20 Nov 2017 Planned End Date changed from 30 Dec 2018 to 14 Jan 2019.
- 07 Jun 2017 New trial record